CENTERS FOR DISEASE CONTROL AND PREVENTION

+ + + + +

OFFICE OF MINORITY HEALTH AND HEALTH Equity + + + + +

HEALTH DISPARITIES SUBCOMMITTEE

+ + + + +

THURSDAY FEBRUARY 2, 2017

+ + + + +

The Subcommittee met by teleconference at 1:30 p.m., Lynne Richardson, Chair, presiding.

PRESENT

LYNNE D. RICHARDSON, M.D., Chair

ANTHONY ITON, M.D., J.D., M.P.H., Senior Vice President, Health Communities, The California Endowment

DAVID FUKUZAWA, M.Div, M.S.A, Program Director for Health, The Kresge Foundation

MARY GARZA, Ph.D, M.P.H, Assistant Professor, University of Maryland School of Public Health GARTH GRAHAM, M.D., M.P.H., President, Aetna Foundation

MARGUERITE RO, Dr.P.H., Chief, Assessment, Policy Development, and Evaluation Section, Public Health, Seattle-King County

WILL ROSS, M.D., M.P.H., Associate Dean for Diversity, Washington University School of Medicine

HECTOR VARGAS, Executive Director, Gay and Lesbian Medical Association, Health Professionals Advancing LGBT Equality

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

CHERI WILSON, M.A., M.H.S., CPHQ, Director, Diversity and Inclusion, Robert Wood Johnson University Hospital

WILMA WOOTEN, M.D., M.P.H., Public Health Officer, County of San Diego Health and Human Services Agency

ALSO PRESENT

MELANIE DUCKWORTH, Ph.D, Senior Advisor to the Director, Office of Minority Health and Health Equity

JEFFREY HALL, Ph.D, MSPH, CPH, Behavioral Scientist, Etiology and Surveillance Branch, Division of Violence Prevention, National Center for Injury Prevention and Control

DAVID HUANG, NCHS, Ph.D., M.P.H., C.P.H., Office of Analysis

LEANDRIS LIBURD, Ph.D., M.P.H., Designated Federal Officer

ANA PENMAN-AGUILAR, Ph.D., Associate Director for Science, Office of Minority Health and Health Equity

JUDY RICHARDS

ANNE SCHUCHAT, M.D., Acting Director CDC/ATSDR

C-O-N-T-E-N-T-S

Roll Call/OMHHE Updates4
Transition Update by Anne Schuchat8
Opening Remarks by HDS Chair Lynne Richardson26
Update on Workforce Diversity Indicator, The National Collaborative for Health Equity, by Ana Penman-Aguilar
Open Discussion68
Public Comment
Adjourn

1	P-R-O-C-E-E-D-I-N-G-S
2	1:31 p.m.
3	DR. LIBURD: So good afternoon,
4	everyone. This is Leandris Liburd. I am the
5	Designated Federal Officer for the Health
6	Disparities Subcommittee, and I will go ahead and
7	start our meeting with the official roll call.
8	Please indicate if you are present when I call
9	your name. Lynne Richardson?
10	CHAIR RICHARDSON: I am present.
11	DR. LIBURD: David Fukuzawa?
12	MR. FUKUZAWA: Present.
13	DR. LIBURD: Mary Garza?
14	(No audible response.)
15	DR. LIBURD: Garth Graham?
16	DR. GRAHAM: Present.
17	DR. LIBURD: LaMar Hasbrouck?
18	(No audible response.)
19	DR. LIBURD: Willie Horner Johnson?
20	(No audible response.)
21	DR. LIBURD: Anthony Iton?

1	(No audible response.)
2	DR. LIBURD: Maureen Lichtveld?
3	(No audible response.)
4	DR. LIBURD: Marguerite Ro?
5	MS. RO: Present.
6	DR. LIBURD: Will Ross?
7	MR. ROSS: Present.
8	DR. LIBURD: Mildred Constance?
9	(No audible response.)
10	DR. LIBURD: Hector Vargas?
11	MR. VARGAS: Present.
12	DR. LIBURD: Donald Warne? Don?
13	(No audible response.)
14	CHAIR RICHARDSON: He might be muted.
15	DR. LIBURD: Okay. Are you on mute?
16	(No audible response.)
17	DR. LIBURD: Okay. We know he is
18	here.
19	PARTICIPANT: Yes, I thought I heard
20	him come on earlier.
21	DR. LIBURD: Yes, he did. Cheri

1	Wilson?
2	MS. WILSON: Here.
3	DR. LIBURD: Wilma Wooten?
4	MS. WOOTEN: Here.
5	DR. LIBURD: I am going to go back
6	and double-check that Mary Garza
7	MS. GARZA: Here.
8	DR. LIBURD: LaMar Hasbrouck?
9	(No audible response.)
10	DR. LIBURD: Willie Horner Johnson?
11	(No audible response.)
12	DR. LIBURD: Anthony Iton?
13	MR. ITON: I am here.
14	DR. LIBURD: Okay. Great. So
15	CHAIR RICHARDSON: Would you read for
16	us Leandris who you have as present?
17	DR. LIBURD: Yes. So I have Lynne
18	Richardson, David Fukuzawa, Mary Garza, Garth
19	Graham, Anthony Iton, Marguerite Ro, Will Ross,
20	Hector Vargas, Don Warne, Cheri Wilson, and Wilma
21	Wooten.

1	CHAIR RICHARDSON: Are there any HDS
2	members whose name Leandris did not just call who
3	are on the line?
4	(No audible response.)
5	DR. LIBURD: So we we have a
6	quorum, and we can begin the meeting, and if any
7	Health Disparities Subcommittee members join,
8	please let us know at a different point on the
9	agenda.
10	CHAIR RICHARDSON: Okay, Leandris.
11	Could we just give an opportunity for any CDC
12	staff or members of the public who are on to
13	identify themselves?
14	DR. LIBURD: Yes. So we can start in
15	this room. This is Leandris Liburd, and I am
16	here with Melanie Duckworth. So who is on the
17	phone?
18	MR. HALL: This is Jeff Hall.
19	MS. RICHARDS: Judy Richards here.
20	Oh, sorry.
21	DR. LIBURD: Okay. Dr. Anne Schuchat

1	has just joined.
2	DR. SCHUCHAT: Good morning.
3	DR. HUANG: Hi. This is David Huang
4	from NCHS.
5	DR. LIBURD: David, great, good
6	morning I mean afternoon. Anyone else?
7	(No audible response.)
8	DR. LIBURD: Okay. Great.
9	CHAIR RICHARDSON: Okay. Thank you,
10	Leandris.
11	So I I did hear that Anne Schuchat
12	is on the phone, so to be respectful of what I
13	can only imagine is her very busy schedule, I
14	think we're going to move right to an update on
15	the transition from Anne, and thank you so much
16	for joining us.
17	DR. SCHUCHAT: Well, thanks so much
18	for inviting me, and thank you for all that you
19	do. I was really pleased to get to meet with the
20	subcommittee last year when you were in town for
21	the last meeting in my role as Principal Deputy

Director, and I am pleased to get to join you by phone today in my new role.

I wanted to share with you some of the internal changes that reflect our temporary -- you know, our transition status. In addition to my serving as the Acting Director for CDC, Pattie Simone has joined us as the Acting Principal Deputy Director. I think many of you will know Pattie from her work leading the division that is focused on training and workforce and her prior work as Principal Deputy Director for our Global Health Group, so she brings a huge amount of experience to our leadership team here.

And then also I'll let you know that Sarah Wiley has joined as the Acting Chief of Staff for CDC. She is usually the Senior Advisor in the Office of Infectious Diseases here, and those of you on the Advisory Committee to the Director will probably remember Sarah, as she served as the Designated Federal Official for the Laboratory Safety Working Group to the Advisory

Committee to the Director, so Sarah will 1 2 Acting Chief of Staff and also in that role serving as the Designated Federal Official to the 3 whole Advisory Committee to the Director. 4 5 You know, the team -- the others that you were familiar with remain in place, with 6 Daniel 7 Katherine Lyon as t.he Lead for Communication and Sherri Berger as our Chief 8 Operating Officer. Karyn Richman is now the 9 Acting Director for our CDC Washington office, 10 and Von Nguyen is leading the Office of the 11 Associate Director for Policy, as John Auerbach 12 13 moved on to the Trust for America's Health, so 14 it's a great team, and we are all interim except for the people who were here before us, but we're 15 16 very pleased to get to work with our advisory 17 committees and subcommittees on the Agency's key work. 18 You know, from my perspective, there 19 20 is a lot of really good work that the Agency has 21 been doing recently on health disparities and

I hope you saw the January Vital 1 equity issues. 2 that was focusing on improvements chronic renal disease among diabetics who are 3 American Indian or Alaska native. 4 We have had 5 actually great progress in the chronic renal disease sequelae among people with diabetes in 6 the tribal communities, and so that was actually 7 a good news story about using best practices and 8 9 models that could be used in other areas.

> We also had a recent MMWR really highlighting rural health and some of the really shocking disparities that were seen in rural areas around the country. That was surveillance summary in the January -- in January for the MMWR, but it was launching a yearlong set of articles about rural health issues, and so that -- one of the equity issues that we really want to be highlighting right now is we have uncovered pretty exceptionally high rates mortality in rural populations.

Next month, we're going to be --

10

11

12

13

14

15

16

17

18

19

actually, this month, wait a minute, February, we're going to be highlighting hearing loss as a major health problem that hasn't gotten that much attention, and that has been a partnership across multiple centers here, but again one where there are some important disparities that we will be signaling. So I think the scientific and programmatic work is continuing, and with high visibility - that is, as highly visible as we can have.

In terms of the information about the transition, I would say that before a Secretary is appointed for HHS, we are pretty much in a holding pattern. I have had several meetings with first the transition team, and now with the incoming -- a small number of staff at the Department of Health and Human Services, but they are really focused on organizationally getting set up and looking -- I would say their priority right now is really looking at regulations that are recently released and not yet implemented or

about to be released so that they can take a look at those. So we don't have a whole lot of direction yet about priorities other than what you can see in the media in terms of the issues related to health reform.

My position as Acting Director is, you know, personally an incredible privilege, and since I have been at CDC for 29 years, it is really kind of exciting to get to do this and represent the Agency and mainly, support the good work going on here, but I don't have information about how long I will be in this role. The key message for you all is that the folks you have been working with are still here, and we are still committed to work closely with you and get the advice that you have.

I wish I knew more, but what I promise to folks inside the Agency and also want to share with partners and advisors is that as I know more, I hope to be able to update people as fully as I can, so that is kind of my -- what I can

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1	tell you, but I am happy to try to answer
2	questions if you have any.
3	CHAIR RICHARDSON: Thank you so much
4	for that, Anne. Are there any questions from
5	any members of the committee?
6	MR. ROSS: This is Will Ross. Dr.
7	Schuchat, thank you. We are privileged to have
8	you here, even in an acting capacity, so thank
9	you.
LO	So in terms of the briefing, the Trump
L1	administration, do you have to wait until the
L2	Secretary is confirmed, or have you had
L3	opportunities to do so beforehand?
L4	DR. SCHUCHAT: We we have been able
L5	to do the high-level what is CDC, and they had
L6	requested some the transition team had
L7	requested some particular briefings on public
L8	health emergencies and how we had dealt with them
L9	in the past, for instance Ebola and the pandemic,
20	and there was a separate briefing on Zika so they
0.1	would know what the gituation was and what to

expect, so that was with the transition team 1 2 prior to the inauguration. 3 inauguration, there is Since the something called a beachhead team that is set up 4 5 at Health and Human Services, some individuals who are going through a Senate confirmation type 6 process, and they are really in the catcher's 7 mitt mode right now of just trying to learn what 8 9 are the actions of the week that they need to know about, and so I have had a couple video 10 conferences with them, but it's not yet at the 11 point of setting priorities or direction. 12 13 MR. ROSS: Okay. Thanks. 14 Hi. This is Marquerite Ro, MS. RO: and Dr. Schuchat, again, thank you for taking the 15 16 time out of your day to join us. So we are hearing a lot I think in the 17 media about the potential for the repeal of the 18 ACA, and I am just wondering whether or not --19 because I don't recall whether or not the CDC 20 21 Office of Minority Health and Health Equity was

that prior to the ACA, and just wondering about what potential impact on funding for the office? I believe DR. SCHUCHAT: t.hat. our office predated the Affordable Care Act. positions were there before that. The funding for the office activities doesn't come through the Affordable Care Act funding. Our Agency does get funds that are called the Prevention and Public Health Fund which actually account for more than 10 percent, I believe it's 12 percent, of our Agency's budget. The Prevention and Public Health Fund was part of the Affordable Care Act, and so there has been some concern that appeal of the Affordable Care Act would impact that fund. The funds are actually used for core or base activities and are not related to health reform,

created under the ACA or whether or not we had

and so that we've been able to signal that for

instance to the transition team that funding is

separate from exchanges and so forth.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1	But the budget horizon really remains
2	to be seen. I think that in terms of the
3	executive orders that have already been publicly
4	made, I think we all really need to be ready for
5	some budget uncertainty and some challenging
6	federal budget times, but I don't have specific
7	information about that. In terms of the office
8	setup, though, we believe that predated the
9	health reform bill.
10	DR. RO: Thank you.
11	CHAIR RICHARDSON: Other questions?
12	(No audible response.)
13	CHAIR RICHARDSON: Really? I am very
14	surprised at this group, although I think we all
15	appreciate that, as you say, we all have to be
16	prepared for a certain level of uncertainty in a
17	number of arenas.
18	With respect to at least the sort
19	of the immediate workings of this committee, do
20	you anticipate that we will meet as usual in the
21	spring in CDC, that all of that is sort of on

automatic pilot until there is a change, or is 1 it in limbo until there is clear direction? 2 SCHUCHAT: Thanks for raising 3 DR. I had meant to include that in my remarks. 4 5 We will be sending a communication out to the Advisory Committee to the Director members soon. 6 We were able to speak with the chair, 7 Fleming, yesterday to talk a little bit about 8 9 that. I think the thinking is we have great 10 members of the ACD and very busy schedules, and 11 12 everybody has held that date in April for the 13 next meeting, so we didn't really want to release 14 it right now. In the back of our minds, though, there was the idea that perhaps if we know that 15 16 we will have a new Director in place, you know, 17 for instance by May, it might be nice to delay the meeting a little bit so that the committee 18 could meet with the new Director. When will we 19 20 know that? Who knows? 21 So what we have decided is to keep the

1	April date for now, to poll people about possible
2	dates in May, but for the time being really plan
3	to go ahead so that we can benefit from their
4	advice. The thinking is that a new Director
5	would benefit from meeting with the advisory
6	committee and vice versa, but if we have an
7	extended period of interim leadership, it would
8	be a great time to hear their perspectives. So
9	I think the meeting planned for April, for now,
10	we're planning to go ahead with it, but it will
11	be a little bit clearer in the message that we
12	send out soon.
13	CHAIR RICHARDSON: Okay. So stay
14	tuned, but at this point, we should all leave
15	those dates on our calendars, okay.
16	I did hear someone else join. Did a
17	member of the Health Disparities Subcommittee
18	just call in?
19	(No audible response.)
20	CHAIR RICHARDSON: Okay. Perhaps it
21	was someone else. Any other questions for Dr.

1 Schuchat?

2 (No audible response.)

3 CHAIR RICHARDSON: Well then, again, like to would 4 thank you. We are 5 appreciative that you did take the time to join us telephonically. We really do appreciate that 6 and do take your participation today as a sign 7 of the importance that the work of this 8 9 subcommittee holds for you, and we are very 10 appreciative of that support, and we look forward to doing whatever we can to support you in your 11 role as Acting Director and then as we all move 12 13 forward into this brave new world.

> Well, DR. SCHUCHAT: let just me thank you, Lynne, and thank the whole subcommittee. I really appreciate what you do outside and what you do for us the on subcommittee. You know, we get really good advice from our advisory group, and it helps us make sure we are on track, so thanks for the time that everybody is putting into this,

14

15

16

17

18

19

20

Leandris, thank you for your leadership of the 1 2 group. 3 CHAIR RICHARDSON: Absolutely. Ι would like to second that shout-out to Leandris. 4 5 Okay. Well, with that, I guess we will release you to go on with what I am sure is 6 a very busy day, and we will move on with our 7 agenda. So I don't have too much in the way of 8 9 opening remarks, and Leandris, is your update on here anywhere, or is it --10 11 DR. LIBURD: Yes, it is, and I do have one thing I wanted to share with the subcommittee 12 13 in terms of an update, which is that we are in 14 the throes of planning our third annual Public Ethics Forum collaboration 15 Health in with 16 Tuskegee University. This year, we are going to It will be May the 19th, and the 17 do it in May. theme will be around women's health and women's 18 health across the life cycle, and so, stay tuned. 19 We will be sharing more. It will be here in 20 Atlanta at the Global Communications Center. 21

1	One of the things I want to just
2	raise, put on the radar for our academic
3	colleagues is that we will be reaching out to
4	academic institutions this time I think in a more
5	targeted way, a more concerted way, to encourage
6	students to participate virtually. We are
7	hopeful that faculty will support their
8	participation by maybe providing some academic
9	credit, having them do some follow-up assignment
10	based on presentations or panels or some of the
11	information that will be coming forward through
12	the forum.
13	So that is my primary update for
14	today, and you will be hearing more from us about
15	this. And
16	(Simultaneous speaking.)
17	DR. ROSS: Hi
18	DR. LIBURD: any questions
19	DR. ROSS: Leandris, this is Will.
20	DR. LIBURD: Yes.
21	DR. ROSS: Regarding prospective

members for HDS, I know you had asked for our 1 2 I submitted some names. What is the time period for actually identifying and having HDS 3 members brought on board? 4 I presume we 5 talking after May sometime, right? Right. DR. LIBURD: Yes, 6 we are getting names and resumes right now along with a 7 letter of recommendation that also comes with the 8 nomination, and we will be making a decision 9 10 let's say in May because the members who are rotating off and those whom we cannot extend, 11 their term ends on June 30th. To give us time to 12 go through all of the processes of onboarding 13 14 subcommittee members, we are accepting their information and nominations now, and hope to have 15 16 people committed by the end of May. CHAIR RICHARDSON: I would like to 17 point out, and correct me if I am wrong, Leandris, 18 that current members, even if their terms are due 19 20 to end in June, continue to serve until their 21 successors are duly appointed and approved. Is

1	that correct, Leandris? I think they went over
2	that at an ACD meeting.
3	DR. LIBURD: Okay. Yes, I know
4	CHAIR RICHARDSON: I just don't want
5	people to think they are going to be allowed to
6	disappear June 30th if we have not yet gotten the
7	new members processed, which I assume may have
8	to await a new Director. I don't know. I don't
9	know if that is something that can happen during
10	the transition.
11	DR. ROSS: My daughter is trying to
12	make me hip, and they said the new word is ghost
13	rather than disappear.
14	(Laughter.)
15	CHAIR RICHARDSON: I see. Thank you
16	for that.
17	DR. ROSS: Sure.
18	DR. LIBURD: Okay. I can certainly
19	confirm that. I think members can be extended
20	for up to 180 days with approval.
21	CHAIR RICHARDSON: Well, I thought

that they continued until their successor was 1 2 confirmed, but there was a limit to how long that could happen. Perhaps it's a year. I don't know 3 if everyone actually knows when their term is 4 5 expiring or who would be rotating off come June, but I would hate to lose momentum because we lose 6 a significant number of our current members and 7 for whatever reason the new members are not yet 8 processed and approved and appointed. 9 10 DR. ROSS: Lynne, that was my point I just was concerned we were going to lose 11 something in the transition. 12 13 CHAIR RICHARDSON: Yes, so --14 DR. ROSS: Take a look at that. 15 CHAIR RICHARDSON: Yes, we will look 16 into the legalities of that and get back to you so that people can sort of know what to expect 17 in terms of whether their service might 18 continuing past June 30th. I think it would be 19 extraordinarily ambitious to believe that 20 21 would have everyone confirmed and appointed by

1	June 30th, although perhaps it would be possible
2	before we met in the fall.
3	DR. LIBURD: Yes, and I can certainly
4	let everyone know their term. We're in the
5	process now of extending several members for
6	another two years. They are aware that they are
7	being extended.
8	CHAIR RICHARDSON: Reappointed?
9	Yes.
10	DR. LIBURD: Yes, and then we can let
11	the members know. Some members have served three
12	terms, and we can't extend them any more.
13	CHAIR RICHARDSON: Right.
14	DR. LIBURD: We'll let those members
15	know as well, and I have actually spoken with a
16	couple of members about their interest in
17	continuing because yes, I do think the
18	consistency is important. I think that this has
19	been an incredibly productive subcommittee, and
20	we certainly don't want to lose any of our
21	momentum.

1	CHAIR RICHARDSON: Absolutely.
2	Okay. So thank you for that, Leandris. So I
3	don't really have much in the way of opening
4	remarks. I think this is a particularly
5	challenging time for those of us who care about
6	health equity specifically and equity in general.
7	I think it is going to be very important for us
8	to think strategically and work collectively to
9	make our efforts to preserve and promote the work
10	that is so important to all of us continues.
11	I think this will be even more
12	challenging than it has been in the past. I
13	think that makes our work even more important and
14	our role as members of a federal advisory
15	committee, again, really very important as a
16	platform that will allow us to observe the impact
17	of various actions and initiatives on the health
18	of the public, and particularly on the diverse
19	populations that are the focus of this committee.
20	So I want to thank you for the work
21	you have done and really issue a call to action

1	for the work that we will now have to do that I
2	think will require certainly vigilance and
3	diligence, perhaps courage, as we continue to
4	work on the things that are important to us. It
5	has been a real pleasure working with all of you,
6	and I look forward to continuing the effort.
7	I will give anybody else a minute if
8	anybody wants to say anything or make any general
9	remarks, but I do want to keep us on time, and I
10	know we're going to have an update on the
11	diversity culture audit that was done at CDC next
12	on the agenda. But does anyone want to make any
13	response? You could just say 'amen' or 'ashe'
14	or whatever you're feeling.
15	DR. WOOTEN: Lynne, this is Wilma Wooten. I
16	don't know if this is the time, Leandris, to
17	bring up the issue that I emailed you about, but
18	it kind of speaks to future and continuation of
19	our efforts.
20	The
21	CHAIR RICHARDSON: So Wilma, I think

1	I know where you're going. I think we actually
2	are going to bring that up later in the agenda -
3	_
4	DR. WOOTEN: Okay.
5	CHAIR RICHARDSON: because that is
6	definitely more than a one-minute conversation.
7	DR. WOOTEN: All right. Thank you
8	very much.
9	CHAIR RICHARDSON: Absolutely,
LO	thanks. Anybody else?
L1	(No audible response.)
L2	CHAIR RICHARDSON: Okay. Is Dr.
L3	James Nelson on the line?
L4	DR. LIBURD: So Lynne, this is
L5	Leandris.
L6	CHAIR RICHARDSON: Yes?
L7	DR. LIBURD: I was just told that Dr.
L8	Nelson had a family emergency that has caused him
L9	not to be able to join us today.
20	CHAIR RICHARDSON: Oh, I am sorry to
21	hear that.

1	DR. LIBURD: Yes, I am too. We just
2	heard about it just within the last 15 minutes,
3	so we will, with your permission, go on to our
4	next presentation
5	CHAIR RICHARDSON: Yes, okay.
6	DR. LIBURD: by Ana.
7	CHAIR RICHARDSON: Okay. So we are
8	now moving to the update on the Workforce
9	Diversity Indicator activity. You all will
10	recall that the CDC was working with the National
11	Collaborative for Health Equity on what I believe
12	was a Robert Wood Johnson-funded effort to look
13	at this, if I have that correctly. But whether
14	I do or not, we will now hear from Ana Penman-
15	Aguilar to tell us the status of that activity.
16	DR. PENMAN-AGUILAR: Thank you,
17	Lynne.
18	There are a couple different aspects
19	to this presentation. One is related to the
20	workforce diversity indicators that we are
21	developing at CDC. The other aspect is more

relates to the National Collaborative for Health 2 Equity. 3 As Lynne mentioned, they are funded 4 5 by Robert Wood Johnson to develop measures, and it's a broad health measurement activity, so it 6 covers many domains. It covers health outcomes 7 both for children and for adults. 8 It covers income, education, employment, 9 physical 10 environment, social environment, housing, safety, and access to quality healthcare, so this 11 is a bit distinct from the workforce diversity 12 13 indicator discussion, so I will start with this. 14 So in response to the recommendation from the subcommittee that we develop indicators 15 of health equity, we did an environmental scan 16 17 of efforts across the country that were doing similar things, and we were very excited by the 18 work of Brian Smedley's group within the National 19 Collaborative for Health Equity, their work on 20 21 the Health Opportunity and Equity Measures

broad, and so I will start with that, and that

1 project.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

So as was mentioned earlier, Dr. David Williams, he is on the advisory committee, and I believe he is the chair. I am also on the advisory committee, and we at CDC have been doing a lot of back-and-forth with the project, connecting -- David and I have been connecting -- he is on the call, David Huang, and I have been connecting them with SMEs, subject matter experts, for the data sources that they're using in projects, because they're using a lot of CDC data.

So just to give little you background, and I did send out a one-pager, the launched project has been to start new conversation about the opportunity gap to develop metrics that can be used to chart progress toward health equity, so the primary goals are reframe the health disparities conversation in the context of health equity and opportunity and to develop a set of broadly accessible measures

1	to illustrate gaps and opportunities to achieve
2	health outcomes.
3	So this is one of the things that was
4	particularly appealing to us about this project,
5	that it really took a new a different look at
6	disparities, not in terms of deficits in health,
7	but in terms of opportunities, and it's also
8	multisectoral in its approach because experts
9	tend to focus on inequities in their field and
10	miss how solutions are interconnected.
11	So the National Collaborative for
12	Health Equity will be developing a framing
13	document that lays out the theoretical framework,
14	a state-level analysis that identifies the
15	magnitude of relative and absolute disparities
16	in health outcomes, and a national-level report
17	that depicts opportunity gaps across the country.
18	So I will pause to see if there are
19	any questions on this particular aspect of the
20	presentation.
21	(No audible response.)

1 DR. PENMAN-AGUILAR: Okay. And I 2 will also add that the idea is that we hope to add value to the collaborative, but we certainly 3 expect that what the collaborative learns and 4 5 develops will be of use to the CDC, and that's the goal - to identify things that they are doing 6 that we may want to incorporate in our work here 7 at CDC. 8 9 CHAIR RICHARDSON: Ana, is there any 10 more detail on the timeline for specific types of measures? 11 Well, they have 12 DR. PENMAN-AGUILAR: 13 done a teaser analysis, so the principal actors 14 have done a teaser analysis, and that was of several indicators of health outcomes, 15 income, 16 and social environment, and that confirms the 17 methodological approach. It showed that they were able to share findings for each indicator and 18 build an indicator profile for a state, and show 19 20 regional patterns. But in terms of the timeline 21 for the overall project, all I really know is

1	that we're talking about within this calendar
2	year.
3	CHAIR RICHARDSON: Okay. Thank you.
4	Are there other questions for Ana?
5	DR. ROSS: Yes this is Will Ross
6	again. I appreciate this much more egalitarian
7	approach on opportunity, an access-based
8	approach. I think it's much more positive.
9	I wanted to hear that, while we are
10	doing this, we're still ensuring there is true
11	intersectionality in designing this framework,
12	and intersectionality relates to our policy
13	advocates and people with the National Centers
14	in D.C., people like Nadine Gracia and others,
15	and so do we feel that we have the right personnel
16	from the policy framework to help drive this? I
17	know you mentioned David Williams, but you didn't
18	mention anyone else.
19	DR. PENMAN-AGUILAR: Oh, it's an
20	impressive list of folks. I wish I could
21	remember more names off the top of my head.

1	CHAIR RICHARDSON: It's on their
2	website, I think.
3	DR. PENMAN-AGUILAR: It is, it is.
4	MR. ROSS: I will go online. Don't
5	worry, I will look for it.
6	DR. PENMAN-AGUILAR: Certainly with
7	David being represented, I can't imagine that
8	intersectionality will be neglected, since he is,
9	very much the person who has advanced
10	intersectionality.
11	We will be looking at ranking
12	indicators by race, ethnicity, income, education,
13	and place, and so there are the ingredients for
14	a robust intersectional look at things.
15	DR. RO: Well, this is Marguerite,
16	and I think this is really great and exciting
17	work, and I think the finding of opportunity is
18	one that also gives hope.
19	I will say that there are so many
20	efforts right now going on around data dashboards
21	and such indicators and particularly ones that

are at a lower level, you know, that address 1 either the county level, or for instance, the Big 2 Cities Health Coalition that NACCHO organizes has 3 developed a data dashboard for big cities, and 4 5 while I think it is helpful to have the state view, really a lot of the innovation and the need 6 to address opportunities happens at a very local 7 level. To the degree that the work can connect 8 to what is happening at a more disaggregated 9 level, I think the better off we will all be. 10 DR. PENMAN-AGUILAR: Yes, and there 11 is also work happening in HHS related to Public 12 Health 3.0, which is also more focused at a 13 14 community level, so we will have a meeting in will definitely 15 April, and Ι bring 16 perspective, and I can bring back information 17 from that meeting. this 18 MS. WILSON: Ana, is Cheri I had a quick question: how do you -- I 19 think maybe many of us have heard about the two 20 21 new bills in the House and Senate that have been

1	proposed that would block federal funds for a
2	federal database on geospatial information to
3	identify community racial disparities. So
4	Marguerite, getting back to what you just said,
5	do we have any idea how that can potentially
6	adversely impact data collection or looking at
7	those data?
8	DR. PENMAN-AGUILAR: I haven't seen
9	that information and I don't have an answer for
LO	you.
L1	MS. WILSON: Okay.
L2	DR. PENMAN-AGUILAR: Yes.
L3	MS. WILSON: Leandris, would you like
L4	me to send that out to you or someone to
L5	distribute to the HDS as something to look at?
L6	DR. LIBURD: Yes, that would be good.
L7	Thank you.
L8	MS. WILSON: Okay. It's all over the
L9	public health list servs, so thank you.
20	DR. LIBURD: I just wanted to add to
21	Will's question

1	CHAIR RICHARDSON: It's a little bit
2	hard to hear you, Leandris.
3	DR. LIBURD: Okay. I just wanted to
4	add in response to Will's question about policy
5	indicators and the HHS Office of Minority Health,
6	they are aware of this activity, very, very
7	interested in it, and I believe they are waiting
8	to have it evolved further before really reaching
9	out to Brian Smedley and his group separately and
LO	his collaborators to talk more about policy
L1	outreach.
L2	DR. ROSS: Thanks, Leandris.
L3	DR. RO: This is Marguerite, I am
L4	thinking about the indicators I don't know if
L5	it would work for Healthy People 2030 because it
L6	isn't done yet, but it would be interesting to
L7	make sure that this work also helps to inform
L8	that next effort.
L9	DR. PENMAN-AGUILAR: Right, and it
20	has begun, and Leandris has been at the center
21	of it, so there will be plenty of opportunity for

1	conversation within the office that can then feed
2	the work of Healthy People 2030.
3	Okay. So I am going to move on to
4	the presentation about indicators of health and
5	healthcare workforce diversity.
6	CHAIR RICHARDSON: Workforce
7	diversity, thank you.
8	DR. PENMAN-AGUILAR: So each of you
9	should have a slide set in email, and I would
10	like you to open it, please. And I will try to
11	remember to ask you to advance slides.
12	So starting with the first slide which
13	you see.
14	CHAIR RICHARDSON: And Ana, it is
15	becoming a little hard to hear you.
16	DR. PENMAN-AGUILAR: We're just doing
17	some technical things in the room here to make
18	sure that you can hear me and that I can view the
19	slides.
20	(Pause.)
21	DR. PENMAN-AGUILAR: So on the second

1	slide, you see a list of folks on the workforce
2	diversity indicator team, and this has been a
3	wonderful and very rewarding effort. This has
4	just been fabulous to have the work of Brittany
5	and Jeff Hall, who is the Deputy Associate
6	Director for Science; David from NCHS; Ramal
7	Moonesinghe, mathematical statistician; myself.
8	The presentation will include problem
9	statement, et cetera. We're on the problem
10	statement slide.
11	So this represents some of the work
12	of our literature review and things that those
13	of us on the phone are well aware of, so it is
14	important that the workforce adequately reflects
15	the population served. We know that by 2042,
16	the country is expected to become majority
17	minority.
18	CHAIR RICHARDSON: Ana, I know I'm
19	having problems
20	DR. PENMAN-AGUILAR: Okay.
21	CHAIR RICHARDSON: hearing. That

1	is much better.
2	DR. PENMAN-AGUILAR: All right.
3	Okay. Now I have two microphones.
4	As I just said, we know that by 2042,
5	the country will be majority minority, yet racial
6	ethnic minority groups remain underrepresented
7	in health and healthcare workforces, so we expect
8	that health disparities will increase if
9	workforce representation does not improve, and
LO	we have noticed that for workforce diversity
L1	measurement and monitoring, the national and sub-
L2	national indicators are limited.
L3	And tying this to CDC's mission, our
L4	mission is to work 24/7 to protect America from
L5	health, safety, and security threats, and this
L6	involves routinely taking the pulse of our
L7	nation, and this includes social determinants of
L8	health and other determinants of health
L9	disparities.
20	So the purpose of this project is to
21	improve understanding of diversity in the U.S.

health and healthcare workforce; assess the state
of diversity; expose measurement gaps; frame
diversity as a social determinant of health that
must be addressed to advance health equity. So
for this reason, we are developing indicators of
diversity through a health equity lens.

This actually builds on a workforce

This actually builds on a workforce diversity indicator that was developed for Healthy People 2010, and it complements the social determinants of health indicators that are in Healthy People 2020, and we anticipate that it will complement the indicators in Healthy People 2030.

This slide shows you that in Healthy People 2010, there was an indicator of diversity, and Dr. David Huang, who is on the call, actually worked on this indicator. It was based on the proportion of members of underrepresented racial and ethnic groups specifically. For example, this slide shows the number of degrees awarded by accredited allopathic medical schools to AIAN

Next slide. 2 objective. So we anticipate that this will help 3 -- it will lead to understanding the state of 4 5 health and healthcare workforce diversity, encouraging actions to improve diversity, and 6 importantly, promoting 7 perhaps more focused actions to improve diversity. 8 It will 9 lead to understanding gaps in what encouraging collection of 10 assessed, new data elements, and I should add perhaps new methods 11 for combining data elements to really look at 12 13 intersectionality promoting consideration of 14 health and healthcare workforce diversity as a social determinant of health. 15 This is also one of the goals. 16 17 And ultimately, this benefits the public because there will be health 18 а and healthcare workforce that is better-equipped to 19 20 improve health, and we expect to reduce health 21 disparities. Next slide, please.

Native persons, so this is one element in the

have conducted an environmental 1 2 scan of datasets measuring health and healthcare workforce diversity. Brittany, who is on the 3 call I believe, has worked with Jeff to develop 4 5 an annotated bibliography. She also developed two justification statements, and have been 6 we conducting key informant 7 and stakeholder consultations. 8 9 And in terms of what is ahead, intend to keep consulting with informants and 10 stakeholders as we develop workforce diversity 11 12 indicators. We are starting with 13 indicator for a diverse workforce. Brittany is 14 putting together spreadsheet а of all the different data sources, and we're looking at the 15 16 strengths and weaknesses of those, and we're thinking about methods for combining data points. 17 And then it will expand to other 18 dimensions of the healthcare workforce. Once we 19 20 have learned what learn from we can

to the

expand

process,

we'll

21

public health

workforce, which will be a bit more challenging, 1 2 and then once we have the indicators developed, we will measure workforce diversity and produce 3 a report with a gap analysis in this calendar 4 5 year. Next slide, please. So I wanted to talk a little bit about 6 what we have learned, and I think having Dr. Jeff 7 Hall and Ms. Brittany Ashkenazi on our team has 8 9 been good because it has allowed us to think about ideally what would we want to know as it 10 relates workforce diversity beyond 11 to Next slide, please. 12 demographics. here you see a slide that was 13 14 shared by the Diversity and Inclusion Management Program within the office. This slide is not 15 16 meant to imply that these elements of diversity 17 carry equal weight. When Dr. David Williams came to CDC 18 to present on diversity and health disparities, 19 20 he presented four different ways of looking at 21 diversity, and I will mention a couple just

1	because I want you to understand that this is not
2	snowflake diversity.
3	Dr. Williams described snowflake
4	diversity as the point of view that we are all
5	individuals just like snowflakes. Because each
6	person is unique, we should not attend to group
7	differences in any substantive way. That is not
8	what we are intending to communicate with this
9	slide.
10	This slide gives the breadth of
11	characteristics encompassed by diversity, and
12	and I think our perspective would follow what he
13	called critical diversity, which is the equal
14	inclusion of people from all backgrounds.
15	So now, Dr. Jeff Hall will talk about
16	aspects of diversity beyond characteristics, and
17	these are other aspects that we would ideally
18	want to measure.
19	DR. HALL: Thank you, Ana.
20	One of the reasons that we wanted to
21	include this next section of slides in the

presentation is to give you an idea of the extent 1 2 to which we are trying to get a good sense of what is involved in the measurement of diversity, 3 as well as give you just a little bit of an idea 4 5 as to how much of a challenge it is that we face when it comes to being able to move this project 6 forward. 7 What you're going to see in the next 8

couple of slides or so are simply an organizing tool. The charts themselves specifically some collective aspects of diversity represent that we saw emphasized and discussed addressed in various ways in the literature, and also identified in a variety of different ways in association with the environment scan that we conducted.

As you might expect, the charts displayed there in the presentation contain the population characteristics that Ana just mentioned in association with the slide provided by the Diversity and Inclusion Office, but also

9

10

11

12

13

14

15

16

17

18

19

20

contain other elements that sometimes don't get 1 considered when it comes to being able to have a 2 more focused conversation about diversity and its 3 4 measurement. 5 So in this respect, what we wanted to do is to provide just an idea of some of the 6 things that spoken 7 were to beyond those population-level characteristics, 8 and specifically, we wish to just give you a brief 9 bit of information about some of the structural, 10 environmental, and competency-related elements 11 that were touched on in various ways in the 12 13 environmental scan. 14 So again, please keep in mind that this literature is very deep and very wide, so 15 16 we wanted to give you just an idea as to some of the things that we saw in terms of the richness 17 of the literature. 18 So as an example of that first box that you see is dedicated to structural 19 characteristics. We saw indicators examined such 20

measures,

and

representational

as

21

this

in

2 representation. And an example of one of the things that obviously has been captured in this 3 domain are measures assessing the proportion of 4 5 professionals from target groups in the workforce a whole as well as in relation to their 6 as presence in specific professions. 7 With respect to concordance measures, 8 9 we saw that the literature also emphasized the 10 necessity of examining the proportion of professionals from target groups in relation to 11 the proportional representation of those same 12 13 target groups in the populations served. 14 And lastly, addressing one additional piece of this box of structural characteristics 15 16 that we're focusing on here, it was emphasized 17 that the presence and nature of inclusioncentered activities such as those focused on 18 retention, recruitment, and training must 19 emphasized. 20 21 One other part that we thought should

respect, that is denoted by the box, for cultural

be brought out in this presentation focuses on organizational the component related to specifically, governance, and more the subsections of literature that we found related to this part felt that it was very critical to examine representation of the entire group, not just in terms of their placement in front-line positions, but also across the various levels and layers and professional tiers as well as within supervisory and board-level positions within organizations different occupational and structures.

We saw in the literature that this was something very highly and strongly that was emphasized because those different levels of professional service have varying levels of involvement where participation in the making of critical decisions is concerned. So that was something that also highlighted was significantly and very directly as a component of the organizational piece that requires some

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1 attention.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

And beyond just simply talking about representation, organizational structures were focused on with respect to characteristics such as the presence of policies, plans, strategies, and agendas that were diversity-focused and the which the organizations extent to in t.he professional context of operations took specific actions to advance or enforce diversity-centered activities. With respect to the next element of

the charts that we present to you, I think we can all agree that it's not just enough to focus on representation or to talk about the organizational structures within which people work. We also have to pay some attention to the actual climate or environment within which the work itself takes place.

So in this regard, some of the various measures of climate or environment that were identified included things such as the actual

movements of members of focal populations and the 1 2 available career paths through organizational structures and within specific professions. One 3 of the ways that this was tapped into was by 4 5 examining the number or proportion of persons promoted from specific targeted groups or that 6 were participating, for example, 7 in specific types of career pathing programs. 8 We also saw and alluded to the fact 9 10 that some emphasis was given to assessing the character of the climate by examining things such 11 the number of formal complaints that were 12 13 submitted as well as obtaining some 14 assessment of employee and management attitudes and practices as it relates to diversity issues. 15 16 So in this respect, beyond population 17 characteristics and beyond structural characteristics, it has been emphasized that the 18 climate is an essential component of what is 19

captured where the measurement of diversity is

concerned.

20

And lastly, we recognize that there 1 2 is significant interest in competence and in how skilled personnel are with respect to the ability 3 culturally 4 to render and linguistically 5 appropriate services. So one specific case of what we saw in the literature related some of the 6 individual staff-level characteristics 7 of persons providing health and healthcare services 8 9 well as organizational characteristics aspects of the national CLAS standards. 10

> And in this particular respect, the type οf domains that were given attention included but were not limited to aspects such as leadership support, which, for example, is assessed by looking at whether organizational leaders and governing bodies actually value patient-centered communication, effective whether the type of commitment that they exhibit something that is considered to be visible to both their lower-level staff as well as the clients that they serve.

11

12

13

14

15

16

17

18

19

20

A second example of one of the domains 1 2 that received emphasis involves community engagement, and some of the questions posed with 3 respect to the measurement aspects in that regard 4 5 included whether or not there is demonstrable progress in terms of proactive efforts designed 6 to effectively engage subgroups in communities 7 where service is being provided. 8 Lastly, language services provision 9 a domain that received focus. 10 particular respect, it was considered to 11 critical to take a look at the extent to which 12 13 language assistance is required and rendered and 14 how this ability of relates to the an organization to meet the needs of its service 15 population. 16 So what we were trying to communicate 17 in terms of providing the final portion of your 18 presentation is a bit of information about the 19 20 complexity of diversity measurement. We're not 21 going to be able to, of course, with this

1	particular project get into all of those
2	different dimensions and all these different
3	aspects. But we wanted to be sure that you were
4	aware that we examined these factors and tried
5	to develop a feasible position with respect to
6	how we would begin to move our project forward.
7	So at this particular point, I will
8	turn the presentation back over to Ana, and we
9	can deal with any additional questions you may
10	have.
11	CHAIR RICHARDSON: Thank you for
12	that. So is that the end of the presentation?
13	DR. PENMAN-AGUILAR: I can wrap up in
14	30 seconds.
15	CHAIR RICHARDSON: Okay, great.
16	DR. PENMAN-AGUILAR: Thank you so
17	much, Jeff, and in terms of challenges we are
18	facing, I would say certainly measurement gaps,
19	places where data are not collected, would help
20	us understand diversity better. Because of this,
21	it will be difficult to get to more than just

1	certain population characteristics.
2	Nevertheless, we are determined to have this be
3	more than a snapshot of race, ethnicity, or race,
4	ethnicity, and sex. We have some ideas that we
5	will test out in the physician indicator
6	development. And another challenge is just
7	continued alignment with stakeholders, so we want
8	to be in conversation with other stakeholders.
9	Thank you.
10	CHAIR RICHARDSON: Are there
11	questions for Ana or Jeff? Maybe I will start.
12	I thank you for this very comprehensive
13	presentation of the deep dive that you have taken
14	into how to think about and look at and assess
15	diversity, particularly in the context of the
16	workforce. Can you maybe talk a little bit now
17	about how you're going to operationalize this
18	very impressive framework into metrics, and what
19	are the next steps?
20	DR. PENMAN-AGUILAR: Well, I would
21	say the first step is to do the teaser analysis

with physician diversity, and a lot of what we can do will be limited by the data that are available. So we will obviously have this entire framework in mind as we look at the data points that we have to work with, and we will try to do justice to the principles behind diversity in our measurement, but it will probably come down to the variables that we have, and we expect that we'll have race, ethnicity, sex, geography, and perhaps, would look age, so we at race, ethnicity, sex, and geography as dimensions of diversity.

I think one of the ways we could even use age or year of graduation from training would be to see whether our cohorts are becoming more or less diverse, so these are just some practical thoughts, and as Jeff said, when it comes down to the practicalities. However, we want you to know that we have not forgotten the other important things that Jeff has just shared with all of us.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1	DR. HALL: And one additional thing I
2	will add and thank you, ladies and gentlemen.
3	I know I flew through the presentation of the
4	nuances of the framework. It helps to be able
5	to lay out a lot of these conceptual parts
6	because, as Ana mentioned, while there are going
7	to be some obvious limitations with respect to
8	what we can do with existing data, but having
9	explored the literature and by beginning to
10	create such a framework, allows us to also begin
11	to develop some aspirational goals with respect
12	to what might be possible to capture if
13	opportunities were to present themselves for
14	example to participate in new measurement
15	activities where diversity is concerned.
16	So the framework that we presented has
17	a lot of stuff in there that is abstract and that
18	might be very difficult to measure within public
19	health or even with respect to specific
20	healthcare professions. But it helps to be able
21	to think through the various pieces of diversity

and parts of diversity that together constitute 1 the environment in which these professionals that 2 render service perform, and it gives us a good 3 position with respect to what we are measuring 4 5 and how that relates to the actual realities that we're trying to change when we're pushing 6 diversity as a social determinant of health. 7 DR. PENMAN-AGUILAR: Yes, and I would 8 9 like to add to that, it's one thing we talk about in our team that what we can't measure may be 10 just as important to understand as what we can 11 What we have done, we have actually 12 measure. 13 created a matrix that has questions that we would 14 want to answer if we had the data, and a lot of times, when you look at the cells that are filled 15 16 in with the data sources, they're empty because the data just don't exist. 17 And, I also don't want to minimize the 18 better importance of doing with population 19 20 characteristics. This is something we have

talked about at other meetings, that we really

1	need to do better as a field with getting to more
2	of the characteristics that are listed in the
3	framework.
4	CHAIR RICHARDSON: Okay. I want to
5	leave some time for the committee members to ask
6	questions
7	DR. ROSS: This is Will Ross. I
8	appreciate Lynne's question about how you are
9	going to operationalize it because, you have
10	quite a lot of data, and I understand that. Jeff,
11	you have mentioned how much of this is abstract
12	and how much of this is going to be spelled out
13	later, but still, we don't have a sense of
14	prioritization.
15	Among these within this framework,
16	are there particular cells or areas that are
17	going to be high priority based on the work that
18	we presented the ACS recommendations we
19	presented a couple years ago? So what will drive
20	prioritization in this effort?
21	DR. PENMAN-AGUILAR: That is a very

good question. I would say that population 1 2 characteristics are definitely a priority. think anything that speaks to decision-making is 3 a priority, since that is in the literature. 4 5 Jeff, do you have anything to add? I do think that, like Ana DR. HALL: 6 said, the population characteristics 7 decision-making piece are priorities. 8 I think part of what we're beginning with is 9 10 limited by where are starting. we In characterizing the existing data sources, we are 11 12 beginning from а position where are essentially working with the 13 decisions that people have made in the past, but what that may 14 do is also create a space where we can then sort 15 16 of say if we only focus at this part, then we're going to be very limited in how we can make 17 movement forward in this particular space. 18 That could in turn give us the ability to evaluate to 19 what extent we could move into the examination 20 21 of some of the other parts of this chart that we

have attempted to lay out for the group today. 1 2 DR. RO: This is Marquerite. I think the schema is really interesting, and it's one 3 of the most organized schemas that I have seen, 4 5 so thank you very much for doing this. I think this is actually in itself a contribution 6 addition to where there isn't data. 7 In terms of an interesting project 8 that we might want to consider that would be 9 another piece of information to add is many 10 states through their Departments of Health have 11 12 workforce plans that they are developing or have developed, and it would be interesting to look 13 14 at -- for somebody like a graduate student or something, it would be interesting to look across 15 state health workforce plans -- and to look at 16 the areas that they touch under these schemas. 17 I am glad you actually 18 DR. HALL: mentioned that because one of the activities that 19 we did do as part of this work, when it came to 20 21 some of the stakeholder conversations, we did experts with respect to the CLAS standards, and in some of those conversations, Dr. Lester did talk to us, for example, about the accreditation boards that exist within public health and how relationships with those types of groups and looking at the work that they do in terms of compliance activities might provide us with some opportunities to get a sense of what is being done on the ground where some of the local health departments are concerned.

Hi. This is Wilma DR. WOOTEN: I am on the public health Wooten in San Diego. accreditation board, and I was thinking along If you could go into how to elevate those lines. or promote it as a national standard, it would with staff be great idea to connect and local public communicate it to health jurisdictions because the workforce development plan is one of the required documents in the application process for a voluntary national

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1	public health accreditation.
2	DR. PENMAN-AGUILAR: Great, and
3	these are the types of intersections that we're
4	wanting to think about right now, and I know
5	Marguerite you had also mentioned some
6	intersections with the de Beaumont Foundation and
7	PH WINS, so we want to ensure that this is
8	aligned, that we're learning from other people,
9	that we offer value to others.
10	DR. WOOTEN: Yes. This is Wilma
11	again. Both of those are organizations that have
12	presented on diversity to the PH WINS project,
13	so it would be really nice to avoid having
14	competing models. They need to be integrated
15	DR. PENMAN-AGUILAR: Okay.
16	DR. WOOTEN: in some way so that
17	jurisdictions locally as well as states,
18	territorial and trial jurisdictions are up to
19	speed about what they should be focusing on. If
20	everybody is in alignment, I think it would be a
21	more coordinated approach, and we'll have overall

1	better outcomes at the local level in the public
2	health jurisdictions monitoring this
3	information.
4	DR. PENMAN-AGUILAR: Yes, and I hear
5	my Director saying yes, yes, so that's a sign
6	that I think we're onto something, and we will
7	be wanting to communicate with others who have
8	similar goals and assure that we're aligned.
9	DR. LIBURD: Wilma, this is Leandris.
10	So we have started conversations with our
11	colleagues here at CDC, Liza Corso, and the
12	Public Health Accreditation Board, and Tiffany,
13	so we will continue to actually raise this issue
14	as well, talking with them primarily about health
15	equity, and it will be on the agenda for our next
16	meeting of the subcommittee, so we will continue
17	this conversation.
18	CHAIR RICHARDSON: Okay, great.
19	Anyone else? We are a little over time, but I
20	think this is an important topic, and it has been
21	a good discussion.

1	DR. GARZA: This is Mary. I just had
2	a quick question: this is really interesting,
3	this framework and everything, and I think this
4	is really a contribution. Is there a timeline
5	when some of these pieces are going to be
6	operationalized and move forward? Do we have a
7	deadline as far as getting this?
8	DR. PENMAN-AGUILAR: We want to have
9	a report, some report, produced by the end of the
10	year, and whether it's a report of a teaser
11	analysis or beyond that, we want to present some
12	data before the end of the year.
13	DR. GARZA: Okay.
14	CHAIR RICHARDSON: Thank you. Anyone
15	else?
16	MR. VARGAS: This is Hector. I just
17	want to add very quickly I concur with what my
18	colleagues are saying about the contribution that
19	this work is doing.
20	Just a suggestion if it is not already
21	included to specifically call out gender identity

1	in the analysis. I am certain that is probably
2	part of the
3	DR. PENMAN-AGUILAR: Absolutely.
4	MR. VARGAS: data gaps, so I think
5	that is important because sexual orientation is
6	already there, and I think that is important.
7	And secondly, just to sort of reaffirm the
8	importance of the gap analysis that you're going
9	to do, and I hope that that gap analysis will
10	include specific recommendations on how we can
11	try to fill in those gaps where data does not
12	exist or very little data exists.
13	DR. PENMAN-AGUILAR: Thank you,
14	Hector, and that is at the very top of our list
15	in terms of gaps, gender identity and sexual
16	orientation.
17	CHAIR RICHARDSON: Okay. Well, thank
18	you, Ana and Jeff. We look forward to continuing
19	to hear on the progress as you move this forward.
20	DR. HALL: Thank you.
21	CHAIR RICHARDSON: And it is very

1	important work and quite promising in the very
2	thorough and comprehensive approach that you have
3	taken.
4	So we have moved down the agenda.
5	We're now at the open discussion period, and so
6	Wilma, I know there is an item that you had wanted
7	to bring to the HDS from the SDOH Think Tank.
8	DR. WOOTEN: Sure, thank you, Dr.
9	Richardson.
10	So the Social Determinants of Health
11	Think Tank had a meeting last Friday, and there
12	was a lot of discussion about making
13	recommendations to the Director or Interim
14	Director. For example, making explicit
15	recommendations about preserving and continuing
16	the health equity and social determinations of
17	health efforts, and identifying strides that have
18	been made, and clarifying why we want to
19	continue.
20	This is an opportunity to present a
21	united voice to push for ensuring that those

1	efforts continue. The discussion was, because we
2	were having this meeting today, to bring the
3	sentiments of the SDOH Think Tank to this group
4	to request that a joint letter or recommendation
5	be developed, and that is the first ask. Does
6	this subcommittee want to do that? And if so,
7	to form an ad hoc group to determine the content,
8	and then that group would also bring back some
9	strategic approaches, whether to send the
10	recommendation to the current Interim Director
11	or wait for the permanent Director to come
12	onboard.
13	There were two components that
14	received a lot of discussion. Particularly,
15	whether it is advantageous to send information
16	now as well as when a new Director comes in, or
17	wait until a permanent Director comes onboard?
18	This is my proposal to the subcommittee.
19	CHAIR RICHARDSON: Comments,
20	discussion? I know some of you will recall we
21	did have a similar discussion at our last meeting

1	about putting together something, whether it was
2	a letter or a report, but something to put in
3	front of the new leadership of CDC, so I think
4	we are very much on the same page with the work
5	group.
6	I guess the questions are: Is this
7	something the HDS wants to move forward with?
8	And should we do it in concert with the Social
9	Determinants of Health Think Tank?
10	DR. Iton: This is Tony Iton. I
11	support that invitation that we should do it in
12	concert with that work group, and I think that
13	we should wait, and I suspect that we won't have
14	to wait that long.
15	CHAIR RICHARDSON: Yes, for a
16	permanent Director of CDC?
17	DR. ITON: Yes.
18	DR. ROSS: This is Will. I agree
19	with Tony Iton. I think that we want to wait for
20	maximal impact and maximal effect, and I do think
21	that we should speak with one voice, and so I

1	would urge us to have a unified document.
2	DR. RO: This is Marguerite. I second
3	that.
4	CHAIR RICHARDSON: Okay. I am
5	definitely hearing a rapidly forming consensus.
6	Leandris, I guess a question I have for you is,
7	or Wilma, if this was discussed, would this be
8	most impactful if the think tank and this
9	subcommittee worked together to create a document
LO	which we then present to the ACD for its
L1	endorsement so that it actually came from the
L2	full ACD rather than the subcommittee and think
L3	tank? Is that
L4	DR. WOOTEN: That was the intent,
L5	Lynne, yes.
L6	CHAIR RICHARDSON: Okay. So
L7	Leandris, if the ACD meeting occurs in April, at
L8	what point would the agenda close? Just so we
L9	know, can we still get onto the April meeting
20	agenda?
01	DR I.TRURD: Yes The agenda doesn't

1	close until generally 30 days before the meeting,
2	and we have had a standing spot on the agenda for
3	the Health Disparities Subcommittee
4	CHAIR RICHARDSON: On the agenda?
5	DR. LIBURD: Yes, on the agenda, so -
6	_
7	CHAIR RICHARDSON: So it could be
8	presented at that time?
9	DR. LIBURD: Yes.
10	CHAIR RICHARDSON: Okay. And it
11	could be also referenced in the field report as
12	well.
13	DR. LIBURD: Exactly, but deferred,
14	that the full report would come with your report.
15	CHAIR RICHARDSON: Very good. Are
16	there any questions or concerns about the course
17	of action upon which we seem to be embarking?
18	(No audible response.)
19	CHAIR RICHARDSON: Anyone?
20	(No audible response.)
21	CHAIR RICHARDSON: All right. So I

1	think now what we need are a couple of individuals
2	who will actually do the work of drafting a
3	document that could then be circulated for review
4	by both groups, presumably. Wilma, do you have
5	a working draft, yet?
6	DR. WOOTEN: No, no working draft. I
7	think we thought about pulling from some of the
8	prior recommendations
9	CHAIR RICHARDSON: Yes.
10	DR. WOOTEN: and then wherever
11	there were any gaps, sentiments that we wanted
12	to move forward, we would include that as well,
13	but our recommendation or suggestion was to form
14	this ad hoc group. I am thinking the chairs of
15	the Social Determinants of Health Think Tank plus
16	the chairs of the subcommittees, STLT
17	Subcommittee and Health Disparities
18	Subcommittee, and anyone else who would want to
19	be involved. We can maybe align it with some of
20	the upcoming meetings, and I know that you have
21	some additional meetings coming up.

1	CHAIR RICHARDSON: Right. Well, I am
2	happy to personally be involved. I certainly
3	would like to have at least one more volunteer
4	from the subcommittee because I do not want to
5	become the rate-limiting step to this process.
6	DR. WOOTEN: Yes, absolutely. And
7	that is a decision that doesn't need to be made
8	now, but could be made
9	CHAIR RICHARDSON: Yes. Well, I
10	actually would like to get a sense of who is
11	interested or willing to volunteer now, and then
12	we can follow up with you and try to convene a
13	meeting of
14	DR. WOOTEN: Absolutely.
15	CHAIR RICHARDSON: whoever it is
16	who is going to be involved and figure out the
17	process and a timeline. Certainly I think we
18	all would like to have this ready to present to
19	the ACD at its April meeting, so I think that is
20	the most important timeline.
21	DR. WOOTEN: Let's just assume that

1	the permanent Director will not be onboard, is
2	that what we're thinking, for April, or do you
3	think that they would be?
4	CHAIR RICHARDSON: No, we think they
5	probably will not be.
6	DR. WOOTEN: Yes.
7	CHAIR RICHARDSON: I guess my thought
8	was that we should have it ready to go to be
9	presented to the Director as opposed to waiting
10	until there is a Director and then starting to
11	write it
12	DR. WOOTEN: Oh
13	CHAIR RICHARDSON: and get
14	DR. WOOTEN: absolutely
15	CHAIR RICHARDSON: ACD approval.
16	DR. WOOTEN: Starting now is
17	absolutely the intent. Where I was going was to
18	make the recommendation to the ACD, and the ACD
19	would present it to the permanent Director when
20	they are onboard.
21	CHAIR RICHARDSON: Yes, that seems to

1	be the strong consensus of the HDS that we would
2	like to wait and present these recommendations
3	to the permanent Director.
4	Okay. Any other comments? I guess
5	we should anticipate for the possibility that we
6	might need to modify them if there is some
7	important change after we have a working draft,
8	but I think that is relatively easy to do, but I
9	don't want to wait and try to get approval at the
10	October ACD meeting because then I feel like we
11	may have missed the opportunity, you know.
12	DR. WOOTEN: I was not even
13	insinuating that.
14	CHAIR RICHARDSON: Right, right, no,
15	I understand, yes. But there is a possibility
16	which was mentioned at the beginning of our call
17	that the April meetings which include both this
18	subcommittee and the ACD might be rescheduled if
19	we are close to having a new Director come onboard
20	because it might be beneficial to have the new
21	Director at the meeting, so right now we are

1	holding the April date, but we will put everyone
2	on notice that the date may change if say by May
3	there would be a new Director in place. Maybe
4	then the ACD meeting would be pushed back, so
5	that's a possibility.
6	DR. WOOTEN: Certainly, but we can
7	still get the work done
8	CHAIR RICHARDSON: Exactly. And I
9	think the bulk of what we're going to say is not
10	going to change over the next few months.
11	DR. WOOTEN: Right.
12	CHAIR RICHARDSON: Okay.
13	DR. RO: Well Leandris, this is
14	Marguerite. I would be happy to join that phone
15	call.
16	CHAIR RICHARDSON: Excellent.
17	DR. ROSS: Well Marguerite, you and I
18	are joined at the hip, and so if you join, I will
19	be there.
20	DR. RO: I think Will and I are two
21	of the departing members, so this can be our

1	parting shot, as it were?
2	CHAIR RICHARDSON: Yes.
3	(Laughter.)
4	CHAIR RICHARDSON: Okay. I don't
5	want to make it too big, and we certainly will
6	take whatever draft is developed and bring it
7	back to the whole HDS. We have another call
8	before April, Leandris?
9	DR. LIBURD: We actually do not.
10	CHAIR RICHARDSON: Okay. Well, I
11	feel though like we could do it by email, and if
12	we have to schedule a call for purposes of
13	discussing this document, then we might be able
14	to do that on an ad hoc basis, but I would like
15	to get input from the entire subcommittee. Well,
16	I guess we would be meeting before the ACD, is
17	that right? Yes.
18	DR. LIBURD: The office can
19	coordinate the calls for the three of you, or
20	however many will be part of the initial writing,
21	and, we can provide a conference call number

1	CHAIR RICHARDSON: Right.
2	DR. LIBURD: so we can have time
3	to get meetings on people's calendars, we just
4	need to confirm from that it is Will, Marguerite,
5	you (Lynne), and I don't know who else?
6	CHAIR RICHARDSON: Whoever is coming
7	from the SDOH Think Tank, and perhaps the
8	DR. WOOTEN: So it would be myself,
9	the chair of the think tank, and then I would
10	imagine we would probably solicit one or two
11	other people, and we'll get that information to
12	you through Judy.
13	CHAIR RICHARDSON: Very good.
14	DR. LIBURD: I think we could get
15	people's schedules within the next month? Okay?
16	CHAIR RICHARDSON: Okay. I do want
17	to take this time to declare the opening of the
18	public comment period. Are there any members of
19	the public on the phone who would like to announce
20	themselves and address the committee at this
21	time?

1	MS. RICHARDS: Lynne, this is Judy
2	Richards. I just wanted to add one piece of
3	information since this is an open time, but the
4	STLT Subcommittee is actually meeting on the 21st
5	of March, so you might want to consider that in
6	your timing. That is all.
7	CHAIR RICHARDSON: Thank you for
8	that. Okay, one more time, here is the
9	opportunity for members of the public who are on
10	the phone who would like to address the
11	committee.
12	(No audible response.)
13	CHAIR RICHARDSON: Okay. I see we
14	are right at the hour, and so I don't want to
15	hold people to make fatuous closing remarks. I
16	think we have heard about some very important
17	initiatives during this call, and we have taken
18	on one action item, which I think we're quite
19	committed to, and we will keep you updated on
20	that and also on any potential changes to the
21	meeting date in April. So unless somebody has

- 1 something else urgent, with that, I will adjourn
- the meeting and bid you all a good afternoon.
- 3 Thank you.
- 4 (Whereupon, the above-entitled matter
- went off the record at 3:01 p.m.)